Hims & Hers said the U.S. FDA's decision that the shortage of Novo Nordisk's weight-loss and diabetes drugs had been resolved ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

The 'Fast Money' traders talk Hims & Hers shares falling despite beat as concerns around weight-loss business escalate.

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as ...

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Josh Lipton takes a closer look at the top stories investors need to know after the closing bell on Asking for a Trend. Hims ...

Hims & Hers (HIMS) stock tumbled 20% post-market after the company released its Q4 earnings report and 2025 guidance amid a ...

Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s ...

The regular session marked a mixed day for Wall Street’s major averages. The Nasdaq Composite ( COMP:IND) dropped 1.2%, while ...

Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth quarter of ...

Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...